-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Good News! A New Specification of Compound Potassium Dihydrogen Phosphate Injection (2 ml) from Shijiazhuang Sihua Pharmaceutical Group Has Been Approved.
Category:
发布时间：2026-01-27
【概要描述】
A new year ushers in a fresh start, with innovation never pausing. On January 26, the supplemental application for the Class 3 chemical drug—potassium hydrogen phosphate injection (2 ml)—developed by Shijiazhuang Sihua Pharmaceutical Group was approved by the National Medical Products Administration and is deemed to have passed the consistency evaluation. This product marks another newly approved dosage form for the Group, following the approval of the potassium hydrogen phosphate injection (5 ml) in January 2025, and represents the second new product the Group has secured since the beginning of this year.
A new year ushers in a fresh start, with innovation never pausing. On January 26, the supplemental application for the Class 3 chemical drug—potassium hydrogen phosphate injection (2 ml)—developed by Shijiazhuang Sihua Pharmaceutical Group was approved by the National Medical Products Administration and is deemed to have passed the consistency evaluation. This product marks another newly approved dosage form following the approval in January 2025 of the potassium hydrogen phosphate injection (5 ml), and it is also the second new product the group has secured approval for since the beginning of this year.
According to available information, potassium hydrogen phosphate compound injection is an inorganic phosphate supplement. This product is primarily used as a phosphate supplement in total parenteral nutrition, such as in patients undergoing moderate-to-severe surgery or other traumatic injuries who require fasting for more than five days; it may also be employed in the management of hypophosphatemia secondary to certain diseases.
The approval of this specification and product variety further enriches the Group’s product pipeline and portfolio, while providing more treatment options for adult and pediatric patients with hypophosphatemia and those receiving parenteral nutrition. To date, the Group has a total of 167 products across 219 dosage forms that have either passed or are deemed to have passed the Consistency Evaluation for Quality and Therapeutic Equivalence of Generic Drugs.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091